Aging with multiple sclerosis and associated prevalence, incidence, comorbidities and healthcare utilization patterns in a population based study Authors: Elsebeth Staun-Ram, Efrat Neter, Lea Glass-Marmor, Nilli Stein, Ariel Miller Published: 2026 ABSTRACT In multiple sclerosis (MS), traditionally considered a disease of predominantly young adults, the growing proportion of aging patients has created an uncharted patient population, whose healthcare needs have not been thoroughly investigated. In this population-based study using the database of the major healthcare organization in Israel, we report the prevalence and incidence of older people with (PwMS), and of people with Rheumatoid Arthritis (PwRA) for comparison, between 2003 and 2022. The increase in MS prevalence in Israel was most pronounced in age group ≥ 60 years, rising from 4.6 to 18.2 per 10,000 people, with the steepest increase observed among older Jewish women. This resulted in an increase in the mean patient age, with PwMS aged ≥ 60 years accounting for 31% of the patients in 2022. Among PwRA aged ≥ 60 years, the steepest increase in RA prevalence was noticed in Arab women. The annual incidence of MS or RA in older patients remained stable during this period. Several comorbidities, including psychiatric and neurodegenerative disorders, stroke and osteoporosis, were more frequent among older PwMS and PwRA, and these patients utilized more healthcare services, including multi-hospitalizations and visits to specialists, than an age- and gender-matched general population. Our study highlighted the phenomenon of growing prevalence of aging PwMS, with gender and ethnicity-specific patterns, emphasizing both the complex medical needs of this aged patient population and the burden of this chronic neurological disease in later life on patients’ quality of life as well as on healthcare systems.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-59022-8. Introduction Multiple Sclerosis (MS), a chronic, autoimmune and neurodegenerative disease of the central nervous system (CNS), mostly makes its first appearance in young adults. It is associated with accumulating disability, with a significant impact on physical function, quality of life, and healthcare costs for both patients and society1. In line with rising worldwide trends in prevalence of autoimmunity2, the prevalence of MS has increased significantly in recent decades3, reflecting, in part, the increased longevity of people with MS (PwMS)4. In some geographic regions, the rise in MS prevalence seems to have been linked to a concomitant increase in MS incidence5–8, mainly attributed to increased awareness of the disease, updated diagnostic criteria and improvement of diagnostic tools, including increased availability of magnetic resonance imaging (MRI) scans. Notably, the increase in prevalence appears steeper among women then in men, which has led to an increased female/male ratio, spanning between 2:1 to 4:1, depending on the region3,8,9. Following increased prevalence, the mean age of PwMS has risen, as well as the proportion of aging PwMS10–12. This emerging group of patients aging with MS, represents a distinct and underrecognized patient population, whose specific needs remain poorly defined and for whom optimal treatment strategies have yet to be established. Older PwMS differ from younger PwMS in their physiological responses and pathological processes. First, immunosenescence is a natural aging process of the immune system, causing progressive compromised immune functionality, which may affect the immune-mediated disease course in aging PwMS and their response to therapy11,13,14. In parallel, the aging brain is subject to significant neurological alterations, including the acceleration of neurodegenerative processes and a decline in brain repair mechanisms. These alterations result in inadequate and deficient recovery processes following a MS relapse, leading to progressive functional deterioration and accumulating disabilities15,16. This is associated with a age-related decline in physical health, estimated to be accelerated by 15–30 years in PwMS compared to the general population17. Second, aging PwMS are also confronted with age-related comorbidities. Third, the safety and efficacy of current available MS disease modifying therapies (DMTs), targeting mainly the immune system, are questionable for aging PwMS, a patient group traditionally not included in the pivotal clinical trial cohorts11,13. In this epidemiological, population-based study, we present the prevalence and incidence of MS in aging PwMS in the Israeli population, based on data from the largest health maintenance organization (HMO) in Israel (‘Clalit Health Services’, CHS). For comparison, we also calculated the prevalence and incidence in aging people with another autoimmune disease- Rheumatoid Arthritis (PwRA). We then compared the frequencies of common comorbidities in aging PwMS and PwRA to an age- and gender-matched group in the general population. Lastly, we described the utilization of various healthcare services of aging PwMS and PwRA, compared to the general population. As the prevalence of MS differs across populations and ethnicities even within the same geographic region18, and since previous epidemiological studies in Israel reported a higher prevalence among the Jewish population compared to the Arab population19, we specifically examined these two major Israeli ethnic groups. To the best of our knowledge, this is the first study to focus on aging PwMS in the Israeli populations, and to comprehensively address the intersection of aging, prevalence, incidence, comorbidity, and healthcare utilization. Results The demographic and clinical characteristics of the study cohorts are presented in Table 1. The overall MS cohort included 5148 PwMS aged ≥ 18 years, who were active members of the CHS database at the end of 2022, of which 1596 PwMS were aged ≥ 60 years old (the MS study cohort). Women comprised 68% of the MS study cohort, consistent with the general MS cohort. In the MS study cohort, the mean age was 69.0 years, with a mean disease duration of 19.3 years and a mean age at diagnosis of 50.3 years. The RA study cohort included 15,079 PwRA aged ≥ 60 years old, 76.7% of whom were women. Their mean age was 74.6 years, with a mean disease duration of 14.3 years and a mean age at diagnosis of 60.3 years. The age- and gender-matched general population cohorts, aged ≥ 60 years, included 6196 individuals in the non-MS cohort, and 60,316 individuals in the non-RA cohort. Following matching, the mean age and sex distribution in the general cohorts were consistent with their respective study cohorts. The MS study cohort included 93% Jews while only 7% Arabs, less than the proportion of Arabs in the general MS population (17.7%), the RA population (16.1%) or the general non-MS or non-RA control populations (14% and 12%, respectively). The representativeness of aging people in the CHS dataset was compared to data from the Israeli National Insurance. Individuals aged ≥ 55 years and aged ≥ 65 years comprised 22.1% and 14.2%, respectively, of the CHS database at 1.12.2022, while these age groups comprised 21.3% and 12.8%, respectively, of the general population in Israel20. Thus, the CHS database is representative of the older population group in Israel. Regarding ethnicity, according to the Central Bureau of Statistics21, Arabs and Jews accounted for 10.7% and 89.3% of the Israeli population aged ≥ 60 years by the end of 2022, respectively. The general control populations from the CHS database align with these proportions, confirming their representativeness of the Israeli population. Table 1Demographic and clinical characteristics.General MS population,age ≥ 18 YStudy cohort: PwMS,age ≥ 60 YGeneral population cohort,age ≥ 60 YStudy cohort: PwRA,age ≥ 60 YGeneral population cohort,age ≥ 60 YParticipants N51481596(*1549)619615,07960,316Age (Y),mean ± SD [range]49.8 ± 16.0 [18–98]69.0 ± 6.9[60–98]69.6 ± 6.9 [60-98]74.6 ± 8.9[60–104]74.6 ± 8.9[60–104]Female, N (%)3503 (68%)1090 (68.3)(*1051 (67.9))4204 (67.9)11,564 (76.7)46,256 (76.7)Ethnicity, N (%)Jews4235 (82.3)1487 (93.2)(*1445 (93.3))5317 (85.8)12,658 (83.9)53,271 (88.3)Arabs913 (17.7)109 (6.8)(*104 (6.7))879 (14.2)2421 (16.1)7045 (11.7)Age at MS/RA diagnosis (Y),mean ± SD [range]50.3 ± 11.6[12–93]60.3 ± 12.4[1–98]Disease duration (Y),mean ± SD [range]19.3 ± 10.4[0.08-73]14.3 ± 9.7[0.05-80]Demographic and clinical characteristics of participants aged ≥ 18 years old, who were active members of the CHS at the end of 2022. The MS study cohort included people aged ≥ 60 years diagnosed with MS. *For comparison of MS to the general population, people diagnosed with both MS and RA were excluded from the MS study cohort. The RA study cohort included people aged ≥ 60 years diagnosed with RA (people also diagnosed with MS were excluded). The general population cohorts consisted of individuals without MS or RA. These control groups were matched by age and sex at a 4:1 ratio to their respective MS or RA study cohorts. CHS, clalit healthcare services; MS, multiple sclerosis; N, number of participants; PwMS, people with MS; PwRA, people with rheumatoid arthritis; SD, standard deviation; Y, years. Table 1Demographic and clinical characteristics.General MS population,age ≥ 18 YStudy cohort: PwMS,age ≥ 60 YGeneral population cohort,age ≥ 60 YStudy cohort: PwRA,age ≥ 60 YGeneral population cohort,age ≥ 60 YParticipants N51481596(*1549)619615,07960,316Age (Y),mean ± SD [range]49.8 ± 16.0 [18–98]69.0 ± 6.9[60–98]69.6 ± 6.9 [60-98]74.6 ± 8.9[60–104]74.6 ± 8.9[60–104]Female, N (%)3503 (68%)1090 (68.3)(*1051 (67.9))4204 (67.9)11,564 (76.7)46,256 (76.7)Ethnicity, N (%)Jews4235 (82.3)1487 (93.2)(*1445 (93.3))5317 (85.8)12,658 (83.9)53,271 (88.3)Arabs913 (17.7)109 (6.8)(*104 (6.7))879 (14.2)2421 (16.1)7045 (11.7)Age at MS/RA diagnosis (Y),mean ± SD [range]50.3 ± 11.6[12–93]60.3 ± 12.4[1–98]Disease duration (Y),mean ± SD [range]19.3 ± 10.4[0.08-73]14.3 ± 9.7[0.05-80]Demographic and clinical characteristics of participants aged ≥ 18 years old, who were active members of the CHS at the end of 2022. The MS study cohort included people aged ≥ 60 years diagnosed with MS. *For comparison of MS to the general population, people diagnosed with both MS and RA were excluded from the MS study cohort. The RA study cohort included people aged ≥ 60 years diagnosed with RA (people also diagnosed with MS were excluded). The general population cohorts consisted of individuals without MS or RA. These control groups were matched by age and sex at a 4:1 ratio to their respective MS or RA study cohorts. CHS, clalit healthcare services; MS, multiple sclerosis; N, number of participants; PwMS, people with MS; PwRA, people with rheumatoid arthritis; SD, standard deviation; Y, years. Demographic and clinical characteristics. 1596 (*1549) Age (Y), mean ± SD [range] 69.0 ± 6.9 [60–98] 74.6 ± 8.9 [60–104] 74.6 ± 8.9 [60–104] 1090 (68.3) (*1051 (67.9)) 1487 (93.2) (*1445 (93.3)) 109 (6.8) (*104 (6.7)) Age at MS/RA diagnosis (Y), mean ± SD [range] 50.3 ± 11.6 [12–93] 60.3 ± 12.4 [1–98] Disease duration (Y), mean ± SD [range] 19.3 ± 10.4 [0.08-73] 14.3 ± 9.7 [0.05-80] Demographic and clinical characteristics of participants aged ≥ 18 years old, who were active members of the CHS at the end of 2022. The MS study cohort included people aged ≥ 60 years diagnosed with MS. *For comparison of MS to the general population, people diagnosed with both MS and RA were excluded from the MS study cohort. The RA study cohort included people aged ≥ 60 years diagnosed with RA (people also diagnosed with MS were excluded). The general population cohorts consisted of individuals without MS or RA. These control groups were matched by age and sex at a 4:1 ratio to their respective MS or RA study cohorts. CHS, clalit healthcare services; MS, multiple sclerosis; N, number of participants; PwMS, people with MS; PwRA, people with rheumatoid arthritis; SD, standard deviation; Y, years. Prevalence of MS over 20 years The prevalence of MS over 20 years (years 2003–2022) was calculated for three age groups: 18–44 years (young adulthood), 45–59 years (middle adulthood) and ≥ 60 years (older adulthood). The prevalence of MS significantly increased in all age groups (p < 0.001 for all), with the steepest increase rate seen in age group ≥ 60 years (β coefficient 0.71 compared to 0.32 and 0.42, respectively, p < 0.001) (Fig. 1A). The prevalence of MS among age group ≥ 60 years (the MS study group) increased significantly between 2003 and 2022 across all sex and ethnic subgroups (p < 0.001), with the most pronounced rise observed in Jewish women (β coefficient 0.99 compared to 0.45–0.51) (Fig. 1B). Among women, the rise in prevalence was significantly steeper in Jews than in Arabs (p < 0.001). While Jewish women also showed a significantly steeper increase compared to Jewish men (p < 0.001), no significant differences were observed between sexes within Arabs, or between ethnicities among men. Fig. 1Prevalence of MS 2003–2022. (A) Graph presenting prevalence of MS per 10,000 alive members of CHO age > 18 years between years 2003–2022. (B) Graph presenting prevalence of MS per 10,000 alive members of CHO age group ≥ 60 years between years 2003–2022, according to sex and ethnicity. (C) Graph presenting prevalence of RA per 10,000 alive members of CHO age group ≥ 60 years between years 2003–2022, according to sex and ethnicity. β- beta coefficient of slope presenting rate of increase. (D) Graph presenting the annual mean age of adult PwMS (≥ 18 years) in the CHS database between 2003–2022, according to sex and ethnicity. Prevalence of MS 2003–2022. (A) Graph presenting prevalence of MS per 10,000 alive members of CHO age > 18 years between years 2003–2022. (B) Graph presenting prevalence of MS per 10,000 alive members of CHO age group ≥ 60 years between years 2003–2022, according to sex and ethnicity. (C) Graph presenting prevalence of RA per 10,000 alive members of CHO age group ≥ 60 years between years 2003–2022, according to sex and ethnicity. β- beta coefficient of slope presenting rate of increase. (D) Graph presenting the annual mean age of adult PwMS (≥ 18 years) in the CHS database between 2003–2022, according to sex and ethnicity. To evaluate whether the increased prevalence is specific to MS or reflects a broader rise in autoimmunity, we also assessed the 20-year prevalence of RA - a more common autoimmune condition- among individuals aged ≥ 60 years, stratified by sex and ethnicity (Fig. 1C). While the prevalence of RA also significantly increased across all sex and ethnic subgroups (p < 0.001 for all), the most pronounced increase was seen among Arab women (β coefficient 7.41 compared to 1.51–2.67). Among women, the rise in prevalence was significantly higher for Arabs than for Jews (p < 0.001). Within both ethnicities, women exhibited a significantly greater increase than men (Jews: p = 0.003; Arabs: p < 0.001, respectively), whereas no ethnic differences were observed among men. Figure 1D presents the mean age of adult PwMS (aged ≥ 18 years) in the CHS database between 2003 and 2022, stratified by sex and ethnicity. During the 20-year study period, the mean age increased by 4.4 and 5.2 years in Jewish men and women, respectively, and by 6.1 and 2.4 years in Arab men and women. The rates of increase were generally comparable across groups, with the exception of Arab women, who exhibited a more modest rise (β coefficient 0.12 compared to 0.22–0.26). Notably, the mean age of Arab men and woman with MS remained consistently lower than that of the Jewish cohort throughout the study period. Reflecting the increase in mean age of PwMS, the proportion of PwMS aged ≥ 60 years within the general MS cohort rose from 21.4% in 2008 and 27.8% in 2015 to 31% in 2022. In contrast, the proportion of patients aged ≥ 50 years remained stable, comprising 48.6% in 2008, 50.3% in 2015 and 48.6% in 2022 (Supplemental Table 1), indicating that the main shift has been in the older (≥ 60 years) age group. To assess whether more patients are diagnosed at late age, e.g. > 50 years (late onset MS, LOMS) or > 60 years (very late onset MS, VLOMS), we compared the age of onset of PwMS aged ≥ 60 years in 2022 to the similar age group in 2010. Results are presented in Table 2 and reveal a significant shift towards earlier diagnosis of MS (p < 0.001). Among this age group, 30% were diagnosed at age > 60 years (VLOMS) in 2010, while VLOMS constituted only 19% in 2022. Likewise, 43% were diagnosed at age 50–60 years (LOMS) in 2010, versus 32% LOMS in 2022. Consequently, the proportions of patients with LOMS or VLOMS in our study cohort have decreased over the past decade. Table 2Age of diagnosis in PwMS, age ≥ 60 years.Age at MS diagnosis2010N = 723% (N)2022N = 1596% (N)P-value(2022 vs. 2010)< 18 years0.7% (5)0.4% (6)p < 0.00118–49 years26% (185)49% (775)50–60 years(LOMS)43% (313)32% (512)> 60 years(VLOMS)30% (220)19% (303)The age of diagnosis of PwMS belonging to age group ≥ 60 years in 2022 compared to 2010, according to the CHS database. CHS, clalit health services; N, number; LOMS, late onset MS; PwMS, people with multiple sclerosis; VLOMS, very late onset MS. Table 2Age of diagnosis in PwMS, age ≥ 60 years.Age at MS diagnosis2010N = 723% (N)2022N = 1596% (N)P-value(2022 vs. 2010)< 18 years0.7% (5)0.4% (6)p < 0.00118–49 years26% (185)49% (775)50–60 years(LOMS)43% (313)32% (512)> 60 years(VLOMS)30% (220)19% (303)The age of diagnosis of PwMS belonging to age group ≥ 60 years in 2022 compared to 2010, according to the CHS database. CHS, clalit health services; N, number; LOMS, late onset MS; PwMS, people with multiple sclerosis; VLOMS, very late onset MS. Age of diagnosis in PwMS, age ≥ 60 years. 50–60 years (LOMS) > 60 years (VLOMS) The age of diagnosis of PwMS belonging to age group ≥ 60 years in 2022 compared to 2010, according to the CHS database. CHS, clalit health services; N, number; LOMS, late onset MS; PwMS, people with multiple sclerosis; VLOMS, very late onset MS. Incidence of MS over 20 years The annual incidence of newly diagnosed PwMS between 2003 and 2022 was calculated for four age groups: <18 years (children), 18–49 (young adulthood), 50–60 (LOMS) and 60 + years (VLOMS) and depicted in Fig. 2A. The incidence of MS, despite fluctuations, appeared to have remained relatively stable the last two decades for all age groups. Figure 2B presents the incidence of MS in age group ≥ 60 years, stratified by sex. The relatively high incidence observed between 2003 and 2006 is assumed to reflect the introduction of the electronic health records (EHR) in CHS about two decades ago. Between 2006 and 2022, the incidence of MS remained relatively stable among individuals aged ≥ 60 years in both sexes. Comparison of incidence rates across 4-year intervals (2003–2007, 2008–2012, 2013–2017 and 2018–2022) revealed no significant differences between men and women aged ≥ 60 years in any analyzed period (Supplemental Table 2). Comparison of incidence rate ratios across the study periods revealed a significant reduction in MS incidence among men in 2018–2022 compared to 2013–2017 (p = 0.042). No significant differences were observed comparing 2018–2022 to 2008–2012, nor were any significantly changes found among women across any period (Supplement Table 3). Longitudinal analysis stratified by ethnicity was not feasible due to the limited number of Arab PwMS aged ≥ 60 years. The incidence of RA between 2003 and 2022 was similarly calculated among PwRA aged ≥ 60 years (Fig. 2C). Apart from the higher incidence rate with the introduction of EHR at the beginning of the study period, RA incidence also remained relatively stable over the last two decades in both sexes. Fig. 2Incidence of MS 2003–2022. (A) Graph presenting the annual incidence of newly diagnosed PwMS per 10,000 alive, adult members of CHS database (≥ 18 years), according to age group, between years 2003–2022. (B) Graph presenting the annual incidence of MS per 10,000 alive members of CHS database age group ≥ 60 years between years 2003–2022, according to sex. (C) Graph presenting incidence of RA per 10,000 alive members of CHS database age group ≥ 60 years between years 2003–2022, according to sex. Incidence of MS 2003–2022. (A) Graph presenting the annual incidence of newly diagnosed PwMS per 10,000 alive, adult members of CHS database (≥ 18 years), according to age group, between years 2003–2022. (B) Graph presenting the annual incidence of MS per 10,000 alive members of CHS database age group ≥ 60 years between years 2003–2022, according to sex. (C) Graph presenting incidence of RA per 10,000 alive members of CHS database age group ≥ 60 years between years 2003–2022, according to sex. Comorbidities in PwMS and PwRA, aged ≥ 60 years We compared the frequency of comorbidities among PwMS or PwRA, aged ≥ 60 years, to age- and sex-matched cohorts in the general population, excluding people with a diagnosis of MS or RA. The comorbidities assessed included neurological diseases, psychiatric disorders, malignancies, infectious, autoimmune and cardiovascular diseases (Table 3). The frequency of malignancies was higher in PwMS, but not in PwRA, compared to the general population (20.5% vs. 15.4%, p < 0.001). Psychiatric disorders such as depression and anxiety were more frequent in PwMS and in PwRA than in the general population (20.7 vs. 11.9%, 18.8 vs. 14.7%, both p < 0.001, and 10.7 vs. 9.1%, 12.4 vs. 10.8%, p = 0.052 (trend) and p < 0.001, respectively). Neurodegenerative disorders such as dementia, epilepsy and Parkinson’s disease were also more frequent in PwMS (6.0 vs. 2.9%, 3.8 vs. 1.3%, both p < 0.001 and 1.8 vs. 1.0%, p = 0.01, respectively), while only epilepsy was more frequent in PwRA (1.9 vs. 1.5%, p < 0.001), compared to the general population. Regarding the frequency of comorbidity with other autoimmune diseases, the pattern was complex: Systemic lupus erythematosus (SLE) was more frequent in PwMS (0.6 vs. 0.3%, p = 0.051, trend) and in PwRA (1.8 vs. 0.3%, p < 0.001), psoriasis was more frequent only in PwRA (5.8 vs. 2.1%, p < 0.001), while diabetes was less frequent in PwMS (25.2 vs. 32.1%, p < 0.001), but more frequent in PwRA (37.3 vs. 33%, p < 0.001). Inflammatory bowel disease (IBD) was more frequent among both PwMS and PwRA compared to the general population (1.94% vs. 1.22%, p = 0.031 and 2.32% vs. 1.64%, p < 0.001, respectively), while a higher proportion of celiac was significant only in PwRA. Regarding cardiovascular comorbidities, ischemic heart disease (IHD), congestive heart failure (CHF) and hypertension were significantly more frequent among PwRA than in the general population (21.8 vs. 16.8%, 7.0 vs. 5.0% and 5.8 vs. 2.1%, respectively; all p < 0.001). Conversely, the frequencies of CHF and hypertension among PwMS did not differ from the general population, while IHD was less frequent in PwMS, although this did not reach statistical significance (13.3 vs. 15.2%, p = 0.055). The prevalence of stroke -including both transient ischemic attach (TIA) and cerebrovascular accident (CVA) - was significantly higher among PwMS and PwRA than in the general population (20.1% vs. 9.2% and 14.0 vs. 11.1%, both p < 0.001, respectively). Notably, obesity was less frequent among PwMS but more frequent among PwRA compared to their respective control cohorts (28.9 vs. 37.5% and 44.2 vs. 37.2%, respectively; both p < 0.001). PwMS and PwRA had more often osteoporosis than the general population (1.43 and 1.42 fold, respectively, both p < 0.001). Table 3Comorbidities in age group ≥ 60 years.% of casesMSRAMS(N = 1549)General population(N = 6196)p-valueRA(N = 15079)General population(N = 60316)p-valueMalignancy20.5%15.4%< 0.00119.0%18.7%nsPsychiatric disorders Depression20.7%11.9%< 0.00118.8%14.7%< 0.001 Anxiety10.7%9.1%0.05212.4%10.8%< 0.001Neurodegenerative disorders Dementia6.0%2.89%< 0.0015.7%6.09%0.053 Epilepsy3.81%1.32%< 0.0011.88%1.50%< 0.001 Parkinson1.81%1.02%0.0101.47%1.59%nsAutoimmunity SLE0.65%0.31%0.0511.80%0.31%< 0.001 Psoriasis2.45%1.92%ns5.82%2.05%< 0.001 Diabetes25.2%32.1%< 0.00137.3%33.0%< 0.001 Celiac0.52%0.35%ns0.46%0.35%0.046 IBD1.94%1.22%0.0312.32%1.64%< 0.001Cardiovacular disorders IHD13.3%15.2%0.05521.8%16.8%< 0.001 CHF4.07%4.28%ns7.05%5.03%< 0.001 Hypertension47.4%48.2%ns60.8%55.6%< 0.001 TIA/ CVA20.1%9.2%< 0.00114.0%11.1%< 0.001 Obesity28.9%37.5%< 0.00144.2%37.2%< 0.001 BMI< 0.001< 0.001 < 2536.3%27.8%26.9%28.5% 25–2037.3%36.7%36.3%37.1% > 3024.2%33.1%35.9%32.0%Osteoporosis25.8%18.0%< 0.00135.4%25.0%< 0.001Comorbidities according to the CHS database. BMI, body mass index; CHF, congestive heart failure; CHS, clalit health services; CVA, cerebrovascular accident; IBD, inflammatory bowel disease; IHD, ischemic heart disease; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TIA, transient ischemic attach. Table 3Comorbidities in age group ≥ 60 years.% of casesMSRAMS(N = 1549)General population(N = 6196)p-valueRA(N = 15079)General population(N = 60316)p-valueMalignancy20.5%15.4%< 0.00119.0%18.7%nsPsychiatric disorders Depression20.7%11.9%< 0.00118.8%14.7%< 0.001 Anxiety10.7%9.1%0.05212.4%10.8%< 0.001Neurodegenerative disorders Dementia6.0%2.89%< 0.0015.7%6.09%0.053 Epilepsy3.81%1.32%< 0.0011.88%1.50%< 0.001 Parkinson1.81%1.02%0.0101.47%1.59%nsAutoimmunity SLE0.65%0.31%0.0511.80%0.31%< 0.001 Psoriasis2.45%1.92%ns5.82%2.05%< 0.001 Diabetes25.2%32.1%< 0.00137.3%33.0%< 0.001 Celiac0.52%0.35%ns0.46%0.35%0.046 IBD1.94%1.22%0.0312.32%1.64%< 0.001Cardiovacular disorders IHD13.3%15.2%0.05521.8%16.8%< 0.001 CHF4.07%4.28%ns7.05%5.03%< 0.001 Hypertension47.4%48.2%ns60.8%55.6%< 0.001 TIA/ CVA20.1%9.2%< 0.00114.0%11.1%< 0.001 Obesity28.9%37.5%< 0.00144.2%37.2%< 0.001 BMI< 0.001< 0.001 < 2536.3%27.8%26.9%28.5% 25–2037.3%36.7%36.3%37.1% > 3024.2%33.1%35.9%32.0%Osteoporosis25.8%18.0%< 0.00135.4%25.0%< 0.001Comorbidities according to the CHS database. BMI, body mass index; CHF, congestive heart failure; CHS, clalit health services; CVA, cerebrovascular accident; IBD, inflammatory bowel disease; IHD, ischemic heart disease; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TIA, transient ischemic attach. Comorbidities in age group ≥ 60 years. Comorbidities according to the CHS database. BMI, body mass index; CHF, congestive heart failure; CHS, clalit health services; CVA, cerebrovascular accident; IBD, inflammatory bowel disease; IHD, ischemic heart disease; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TIA, transient ischemic attach. Health care utilization among PwMS and PwRA, aged ≥ 60 years Comparison of the healthcare use between PwMS, PwRA and the general population is presented in Table 4. Within the last three years (2019–2022), PwMS and PwRA aged ≥ 60 years visited more frequently their GP (42 vs. 30 visits and 46 vs. 33 visits, respectively), infection specialists or urologists, compared to their matched general populations (all p < 0.005). PwMS consulted orthopedists or ENT specialists less frequently than the general population (46.4 vs. 50.5%, p = 0.004 and 36.7 vs. 39.6%, p = 0.048, respectively), whereas these specialists were utilized more frequently by PwRA (61.4 vs. 51.4% and 49.2 vs. 42.5%, respectively; both p < 0.001). High-frequency ER utilization (≥ 3 visits within the last three years) was significantly more prevalent among PwMS and PwRA than in the general population (9.6 vs. 6.8% and 12.3 vs. 7.4%, respectively; both p < 0.001,). Similarly, the rates of high- frequency hospitalization (≥ 3 admissions within 3 years) were significantly elevated in both PwMS and PwRA compared to the general population (13.4 vs. 5.9% and 14.2 vs. 8.1%, both p < 0.001, respectively). PwMS and PwRA were more frequently defined as a person with disability compared to the general population (32.7 vs. 7.1% and 17.2 vs. 12.3%, respectively; p < 0.001), and a higher percentage of PwMS and PwRA had engaged in at least one rehabilitation process within the last three years (3.3 vs. 0.5% and 1.0 vs. 0.7%, p < 0.001). Moreover, a significantly higher proportion of PwRA had been referred to a pain clinic compared to the general population (5.6 vs. 2.8%, p < 0.001), whereas no difference was observed among PwRA. Table 4Healthcare utilization in age group ≥ 60 years.Cases N (%)MSRAMS(N = 1549)General population(N = 6196)p-valueRA(N = 15079)General population(N = 60316)p-valueGeneral practitioner median (IQR)42 (28; 59)30 (18; 44)< 0.00146 (31; 65)33 (21; 48)< 0.001Hospitalization< 0.001< 0.0010884 (57.1)4451 (71.8)8073 (53.5)39,973 (66.3)1–2458 (29.6)1378 (22.2)4864 (32.3)15,477 (25.7)≥ 3207 (13.4)367 (5.9)2142 (14.2)486 (8.1)ER visits< 0.001< 0.0010828 (53.5)3950 (63.8)7551 (50.1)36,699 (60.8)1–2572 (36.9)1826 (29.5)5669 (37.6)19,164 (31.8)≥ 3149 (9.6)420 (6.8)1859 (12.3)4453 (7.4)SpecialistENT569 (36.7)2446 (39.6)0.0487413 (49.2)25,662 (42.5)< 0.001Urologist290 (18.7)821 (13.3)< 0.0012612 (17.3)8248 (13.7)< 0.001Orthopedist719 (46.4)3127 (50.5)0.0049251 (61.4)31,002 (51.4)< 0.001Infectiologist14 (0.9)22 (0.4)0.005128 (0.8)266 (0.4)< 0.001Pain clinic48 (3.1)176 (2.8)ns851 (5.6)1694 (2.8)< 0.001Rehabilitation51 (3.3)29 (0.5)< 0.001152 (1.0)398 (0.7)< 0.001Disability507 (32.7)437 (7.1)< 0.0012591 (17.2)7430 (12.3)< 0.001Number of cases with 0, 1–2 or ≥ 3 hospitalizations or visits to ER, and number of cases with at least one visit to a specialist, within the last three years (2019–2022) according to the CHS database. For general practitioner, the median number of visits within the last three years. Disability – bedbound, homebound or requires assistance with ambulation. CHS, clalit heath services; ENT, ear, nose and throat physician; ER, emergency room; IQR, interquartile range; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis. Table 4Healthcare utilization in age group ≥ 60 years.Cases N (%)MSRAMS(N = 1549)General population(N = 6196)p-valueRA(N = 15079)General population(N = 60316)p-valueGeneral practitioner median (IQR)42 (28; 59)30 (18; 44)< 0.00146 (31; 65)33 (21; 48)< 0.001Hospitalization< 0.001< 0.0010884 (57.1)4451 (71.8)8073 (53.5)39,973 (66.3)1–2458 (29.6)1378 (22.2)4864 (32.3)15,477 (25.7)≥ 3207 (13.4)367 (5.9)2142 (14.2)486 (8.1)ER visits< 0.001< 0.0010828 (53.5)3950 (63.8)7551 (50.1)36,699 (60.8)1–2572 (36.9)1826 (29.5)5669 (37.6)19,164 (31.8)≥ 3149 (9.6)420 (6.8)1859 (12.3)4453 (7.4)SpecialistENT569 (36.7)2446 (39.6)0.0487413 (49.2)25,662 (42.5)< 0.001Urologist290 (18.7)821 (13.3)< 0.0012612 (17.3)8248 (13.7)< 0.001Orthopedist719 (46.4)3127 (50.5)0.0049251 (61.4)31,002 (51.4)< 0.001Infectiologist14 (0.9)22 (0.4)0.005128 (0.8)266 (0.4)< 0.001Pain clinic48 (3.1)176 (2.8)ns851 (5.6)1694 (2.8)< 0.001Rehabilitation51 (3.3)29 (0.5)< 0.001152 (1.0)398 (0.7)< 0.001Disability507 (32.7)437 (7.1)< 0.0012591 (17.2)7430 (12.3)< 0.001Number of cases with 0, 1–2 or ≥ 3 hospitalizations or visits to ER, and number of cases with at least one visit to a specialist, within the last three years (2019–2022) according to the CHS database. For general practitioner, the median number of visits within the last three years. Disability – bedbound, homebound or requires assistance with ambulation. CHS, clalit heath services; ENT, ear, nose and throat physician; ER, emergency room; IQR, interquartile range; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis. Healthcare utilization in age group ≥ 60 years. Number of cases with 0, 1–2 or ≥ 3 hospitalizations or visits to ER, and number of cases with at least one visit to a specialist, within the last three years (2019–2022) according to the CHS database. For general practitioner, the median number of visits within the last three years. Disability – bedbound, homebound or requires assistance with ambulation. CHS, clalit heath services; ENT, ear, nose and throat physician; ER, emergency room; IQR, interquartile range; MS, multiple sclerosis; ns, non significant; RA, rheumatoid arthritis. Discussion In this study of aging PwMS among the Israeli population over the last two decades, we found a general increase in MS prevalence, which was especially pronounced for age group ≥ 60 years and steepest among older Jewish women. Annual MS incidence remained relatively stable throughout these years. The proportion of aging PwMS had increased, as demonstrated also by a rise in mean age of PwMS, which was lower in Arab compared to Jewish PwMS. A similar pattern emerged among aging PwRA: stable incidence yet increasing prevalence, here more pronounced among Arab women. Moreover, we showed that several comorbidities were more common in aging PwMS and PwRA, and that these patients utilized more healthcare services, including multi-hospitalizations and visits to specialists, compared to an age- and gender-matched general population. According to data from the 3rd edition of the Atlas of MS, by 2020 the global MS prevalence had increased to 35.9 per 100,000 people, representing an 30–80% increase since 2013 across world regions, with estimated 2.8 million PwMS worldwide3. In high-prevalence regions like Denmark, MS prevalence increased from 22 to 295 per 100,000 people between 1950 and 202322. Increased prevalence has also been reported in Middle Eastern countries, which are generally characterized by low-to-moderate prevalence rates3,23–25. In a Canadian study, the most pronounced increase in prevalence between 1996 and 2013 occurred in the > 50-year age group26, consistent with our observation that the greatest rise in prevalence occurred in aging PwMS. Moreover, reports from various regions have shown how the peak prevalence age group has shifted to older age groups, following the increased prevalence of aging PwMS3,13. Increased MS prevalence can result from augmented incidence rate, prolonged survival and longer lifespan. The global incidence of MS was 2.1 per 100,000 persons/year in 2020, following a significant increase during the past 50 years throughout the world3,9,27, mainly attributed to growing awareness of MS, updated diagnosis criteria, increased availability of MRI scanners and MS specialist, leading also to earlier diagnosis11,27. Within the last 10–20 years, the incidence rate has remained relatively stable in several world regions22,25,26,28–30, similar to our observation in the Israeli population. In contrast to the observed reduced proportions of LOMS and VLOMS patients in the Israeli population during the last decade, studies from other geographical regions found an increase in LOMS over decades31–33. It remains unclear whether the discrepancy between these reports and our study reflects differing study periods and a more recent stabilization in MS incidence, or if is primary population-dependent. Consequently, further epidemiological studies are warranted to determine the longitudinal trajectory of LOMS’ incidence11. However, updated diagnosis criteria and improved availability of diagnostic tools and MS specialists support earlier diagnosis. Moreover, the inclusion of symptoms onset up to age 50 (until 1983) or age 59 (until 2001) in former MS diagnostic criteria34,35, may explain some of the increase in LOMS over the last three-four decades, since the age of onset criteria was annulled. Of notice, the mean age at MS diagnosis of the MS study group aged ≥ 60 years was relatively high (50 ± 12 years, range 12–93), while in MS, historically, first symptom is often presented at age 20–40 years36. It is plausible that the relatively high mean age of diagnosis in these older patients reflects both the evolution of MS diagnostic criteria from the Poser criteria to successive McDonald revisions37–41 and the integration of MRI, which substantially improved sensitivity and specificity of diagnosis. These developments promoted diagnosis also of patients with subtle or atypical presentations, that may have had longstanding, previously unrecognized disease. Supporting this, a 60- year follow-up of PwMS in Norway showed that the time interval between onset and diagnosis of MS declined from a median of 21 years in 1953–1957 to 1.3 year in 2003-200742. The lifespan of PwMS has increased during the last decades, and today, the life expectancy of PwMS is close to the general population, with an estimated reduction of 6–10 years4,10,11,14,27,43. Prolonged life expectancy is attributed to the development of a variety of MS-DMTs, better healthcare and supporting systems, improved diagnostic tools leading to earlier diagnosis and treatment initiation delaying disease progression, in addition to enhanced survival of comorbidities and extension of life span of people in general13,26. Prolonged life expectancy of PwMS is associated with a significant increase in both the mean age and proportion of older patients, as demonstrated in the present study, where in 2022 a third of Israeli PwMS were > 60 years old. This is corroborated by the reports that half of the Danish MS population was > 50 years old in 202344. Furthermore, a US study found that age-specific MS prevalence in 2010 was highest in the 55–64 year age group, followed by the 65–74 year group45. As the proportions of LOMS and VLOMS did not increase in our study cohort in the last decade, the increased proportions of patients aged ≥ 60 years, alongside a stable proportion of patients aged ≥ 50 years, is likely attributable to a extended lifespan. In the present study, the mean age of PwMS in 2022 in the Jewish population was 51–52 years with no notable difference between sexes; this is comparable to the mean ages of 54.2 years and 57.3 years reported in Danish PwMS (2023)22 and Australian PwMS (2022)46. In contrast, the mean age of PwMS in the Arab population in our cohort was notably lower, at 40 years for women and 43 years for men. Furthermore, the rate of increase in mean age over the 20-year period was lower among Arab women compared to Arab men or compared to both sexes in the Jewish cohort. Age-related prevalence differences between ethnicities within a geographic region have previously been reported. For example, in the US, prevalence clearly differed between Hispanic, non-Hispanic-white, non-Hispanic-black and other non-Hispanic people in age groups between 35 and 64 years, while in age groups < 35 or > 64 years the prevalence rate seemed less associated with ethnicity18. In the Israeli population, it has been well established that the prevalence is higher in the Jewish population compared to the Arab population19, but the difference in mean age has not been reported before. Recent studies among Palestinian Arabs24 and Lebanese Arabs47 reported mean ages for PwMS comparable to that observed in our Arab cohort. On a global level, a relatively low mean age of Arab PwMS could be attributed to increasing incidence following improved healthcare services, a high fertility rate contributing to a young population, as well as a shorter lifespan48, driven in part by a high prevalence of smoking49. The lower proportion of older Arab individuals in Israel relative to the Jewish population50 partially explains the lower proportion of Arab PwMS aged ≥ 60 years in our cohort. Additional factors contributing to these sub-population disparities may include genetic variations51,52 and population-specific differences in microbiome composition53. Another recent study based upon the CHS database found that within the last decade, MS incidence among Arab women increased steeply54. As MS is typically diagnosed in young adults, a rising incidence may increase the proportion of these young patients, thereby accounting for the more modest increase in mean age observed among Arab women with MS. Similar to MS, we found that RA prevalence has increased in the Israeli population during the past two decades, concordant with reports on increased global RA prevalence55–57. RA is a systemic chronic autoimmune disease characterized by joint inflammation, with disease onset commonly around age 50 and older55,57, and consequently, the proportion of PwRA ≥ 60 years in the CHS database was much higher than that of PwMS. The RA study cohort demonstrated a relatively stable incidence of RA. While global incidence of RA increased between 1990 and 201956, a stable rate has also been reported in the US population during recent decades58, mirroring our observations. Notably, among PwRA aged ≥ 60 years, the most pronounced increase in RA prevalence was observed among Arab women. Like MS, RA affects women more than men, with a global female to male ratio of 2.45 in 202055. In the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) study, prevalence rates increased by 50% between 1990 and 2020 in the Middle East region and North Africa, a growth rate that substantially exceeds those reported in other geographical areas55. Moreover, RA prevalence in the Middle East and North Africa in 2019 peaked among women aged 60–64 years and among men aged 65–69 years59. The notably higher rate of increase in RA prevalence among Arab women, in contrast to the higher rate of increase in MS prevalence among Jewish women, may reflect differences in mean age of onset and peak prevalence between these two conditions, alongside ethnicity/population- specific variations in lifestyle, lifespan and population growth rates. The proportion of aging PwMS is expected to increase even further in the coming decades. The long-term effect on life expectancy driven by expanded MS-therapeutic options of the past 20 years, alongside the implementation of earlier and more highly effective treatment strategies to prevent disability progression60–62, is anticipated to become even more evident as the aging patient population increasingly benefits from these advancements22. Aging PwMS, coping with prolonged illness duration, accumulating MS-related disability, reduction in cognitive function and in quality of life, also face age-related comorbidities. In our study cohort, aging PwMS exhibited a higher frequency of comorbidities compared to the general aging population, both in psychiatric disorders such as depression, neurodegenerative disorders like epilepsy, dementia or Parkinson, cardiovascular diseases (CVDs) like stroke, autoimmune diseases like SLE and IBD and malignancies. This is consistent with several previous reports on infections, malignancies, CVDs, additional autoimmune diseases, psychiatric disorders and epilepsy being more common in PwMS than in the general population44,63,64, although substantial heterogeneity of estimates was observed among studies65. A large-scale US study of PwMS aged 18–64 years found that the elevated prevalence of CVDs in PwMS was most pronounced among younger patients64, suggesting age-specific variations in comorbidity risk in MS. The increased frequency of osteoporosis in aging PwMS observed in the current study aligns with previous reports and is primarily attributed to glucocorticoid use, progressive immobilization and vitamin D deficiency66,67. Notably, we observed significantly lower percentages of obesity and diabetes, as well as a trend toward a lower percentage of IHD, in aging PwMS compared to the general population. Data on the prevalence of vascular diseases and diabetes in PwMS have been contradictory68. Consistent with our observations, a US study of PwMS aged 40–84 years found lower rates of IHD and myocardial infarction, but increased rates of ischemic stroke, compared to the general population69. A Danish study found a small enhanced risk of CVD in PwMS, which decreased over time70, emphasizing that estimates of comorbidity risk in aging PwMS may differ from that of younger cohorts. The lower frequency of obesity in aging PwMS observed in our study may be linked to the lower frequencies of diabetes and IHD, as obesity is an established risk factor for both disorders71. Previous findings on the prevalence of diabetes in PwMS are inconsistent; while a Canadian72 and a UK study63 reported rates similar to controls in age group > 60 years or in general (respectively), a Danish study44 found higher rates in PwMS aged > 50 years and an Iranian study73 observed lower rates across all age groups-including those > 65 years. Studies on cancer risk in PwMS have also yielded conflicting results74–77. Increased risk has been reported for cancer of the urinary system and brain/CNS, perhaps reflecting a surveillance bias, as PwMS perform regular brain MRI as part of their clinical follow-up, and are often referred to urologists, due to bladder dysfunction being a common symptom in PwMS76,77. Moreover, increased risk of developing cancer in respiratory and genital organs, breast, and the digestive system were reported in some population-based studies75,76, while in other reports PwMS had a lower risk for genital organ (ovarian, testicular), prostate, breast or colorectal cancers74,77. PwMS may be more susceptible to cancer due to persistent inflammation and long-term use of DMTs, especially of immunosuppressants. Careful screening and regular monitoring should be an integrated part of the clinical follow-up. Interestingly, In a study based upon the national French health care database, elevated cancer risk was observed in PwMS < 55 years, while in patients > 65 years the cancer risk was lower compared to the control population74. Since many of the differences in comorbidity frequency observed between PwMS and the general population are likely driven by accelerated aging processes occurring in PwMS78, these discrepancies may diminish in older patients as age-related physiological changes eventually converge with those of the general population. The healthcare utilization patterns among PwMS reported here likely arise from MS-related disabilities and the increased burden of age-related comorbidities relative to the general population. Our data indicated an increased use of emergency departments and hospitalizations, higher utilization of both GP care and various medical specialists, and a greater reliance on long-term healthcare services (e.g., rehabilitation and disability services) compared to the general population. A similar trend was observed among PwRA, emphasizing the burden of chronic autoimmune diseases on healthcare services. Our findings align with previous reports from other countries and health systems44,79–81, further validating the impact of aging with MS on healthcare services utilization. The observed increased frequency of aging PwMS visiting an urologist can be attributed to the well-established high incidence of bladder dysfunction and urinary infections in MS82. Similarly, the higher frequency of visits to specialists of infectious diseases can be attributed to the elevated risk of infections in PwMS83, driven by both immunoscenescent processes and the immunomodulatory or immunosuppressive effects of MS -DMTs84. Of notice, we found that aging PwMS less often visited an orthopedic or an ENT specialist compared to the general population. Given that mobility impairment and consequent accessibility challenges are hallmarks of disability in MS, certain musculo-skeletal symptoms may be managed directly by the treating, and often more accessible, MS specialist, including referral to physiotherapy and rehabilitation. This integrated approach may reduce the need for separate consultations with orthopedic specialists, including those for age-related symptoms. In contrast, the more frequent consultations with orthopedic specialists among PwRA may be attributed to the fact that orthopedic surgical intervention is often an integral component of RA treatment strategy, aimed to restore joint motion and function following damage caused by RA activity85. With aging, immunosenescence becomes a central biological process that contributes to disease activity. The hallmarks of immunosenescence, altering both the innate and adaptive immune systems, include chronic low-grade inflammation named “inflamm-aging” driven by senescent peripheral and CNS resident immune cells, telomere attrition and systemic release of pro-inflammatory, CNS-penetrant molecules from the aging microbiome through a leaky gut15,86,87. PwMS and PwRA are characterized by accelerated immunosenescence15,86,88,89. However, the clinical implications of immunosenescence may vary significantly across different autoimmune diseases, promoting neuroinflammation and neurodegeneration in MS16, while facilitating a pro-inflammatory environment within joint tissues in RA89. This variation may explain some of the differences found between PwMS and PwRA in the present study. Tailoring therapeutic interventions to the special needs of aging PwMS represents a significant clinical challenge. The efficacy of immunomodulatory MS-DMTs seem to strongly decline with age90 likely due to immunosenescence processes, together with the age-dependent transitioning from an inflammatory-mediated relapsing disease course to a progressive course. In parallel, safety considerations regarding medication-related adverse events become increasingly pronounced with advanced age; the primary concerns include serious infections and malignancies91,92, as well as polypharmacy, more likely to occur with age-related comorbidities86,93. The pivotal clinical trials of existing MS-DMTs classically excluded patients > 55–60 years. Therefore, a systematic assessment of drug efficacy and safety in older PwMS is warranted. This includes both the optimal treatment-initiation strategies for patients with LOMS -who often exhibit accelerated disease progression94 - and long-term treatment strategies (e.g. continuation versus discontinuation) for aging patients, alongside the management of polypharmacy and comorbidities. Given the increased prevalence of co-morbidities and higher healthcare utilizations among PwMS, MS centers should consider a multidisciplinary approach. Incorporating additional medical specialists to address the comprehensive needs of the aging PwMS - including comorbidity management and care coordination79 - would facilitate a shift from a single-disease focus toward integrated, tailored therapeutics. A limitation of this study is the analysis of data from a single, though major, HMO, whereas data from national-based databases may better represent a population. Moreover, the epidemiological analysis was focused on 20 years, including the initial years of EHR introduction, with a potential bias regarding registered date of MS diagnosis. Another limitation is the low number of older Arab patients in the database, which did not enable ethnicity-based analyses over time. The strengths of this study include the longitudinal, population-based analysis, including both community-level and tertiary care. Moreover, this comprehensive analytical framework - incorporating prevalence, incidence, comorbidities, and healthcare utilization - facilitates the integration of findings to elucidate the clinical consequences and suggested implications. In conclusion, our study highlighted the phenomenon of an ongoing demographic shift: The MS population pyramid, once heavily weighted toward youth, is demonstrating a growing proportion of people aged 50/60 and beyond, with considerable and unique medical needs. Our findings confirm a consistent global increase in the prevalence of MS, while shifts in MS incidence appear to be primarily regional. The increasing proportion of aging PwMS requires clinical attention, as well as research focus, to optimize healthcare and improve function and wellbeing in this vulnerable group. Methods This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Carmel Medical Center (0006-23-CMC). The study was based upon retrospective administrative and clinical data obtained from the HMO database, with no direct patient contact; therefore the requirement for informed consent was waived by the IRB (Helsinki Committee) of Carmel Medical Center, Israel, in accordance with institutional and ethical guidelines. Clinical and demographic data of the participants was retrieved from the database of ‘Clalit Health Services’ (CHS), the largest HMO in Israel. PwMS (age ≥ 18 years) were identified by the International Classification of Diseases (ICD) diagnostic code of MS (ICD-9 code 340), or by at least one medication withdrawing of a MS-specific DMT (N = 5148). DMTs included: Alemtuzumab, Cladribine, Dimethyl Fumarate, Diroximel Fumarate, Fingolimod, Glatiramer Acetate, Interferon β-1a, Interferon β-1b, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon β-1a, Siponimod or Teriflunomide, prescribed exclusively for MS in Israel. The combination of either of these two criteria was recently recommended for identifying PwMS within the CHS database, providing 87% positive predictive value, 92% sensitivity and 90% specificity95. The MS diagnosis registered in the electronic database is based upon a diagnosis established by a neurologist prior to or during the study period; it follows contemporary diagnostic criteria and was reconfirmed using revised criteria at subsequent clinical visits38–41. For comparison with an additional autoimmune disease, a cohort of PwRA (age ≥ 18 years) was identified using ICD code 714. The MS and RA study cohorts were limited to people aged ≥ 60 years (N = 1596 and N = 15079, respectively). General population cohorts (controls), comprised of people from the national HMO/CHS database without MS or RA, aged 60 years or older as of 31/12/2022, were randomly selected using frequency matching by birth year and sex, using a 4:1 ratio for the MS study cohort and the RA study cohort, separately. Statistical analysis For demographic and clinical characteristics of participants, continuous variables were summarized with mean ± standard deviation (SD), and categorical variables were presented as numbers and proportions. Comparison of demographic or clinical characteristics between the MS or RA study cohorts and their respectively control cohorts, were analyzed using the Chi square test for the categorical variables and independent t- test, or Mann-Whitney, as appropriate, for the continuous variables. Age at MS diagnosis in PwMS ≥ 60 years was compared across time periods using the Chi square test. Prevalence of MS (≥ 18 and ≥ 60 years) or RA (≥ 60 years) over time was calculated as the number of cases at each time point, dated 31/12 of each year, divided by the total population at risk (active CHS members from similar age group) at the corresponding time. Prevalence rates ratios were calculated for comparing differences in time periods, using the Chi square test. Similarly, prevalence rates ratios were calculated according to sex and ethnicity (Jews or Arabs) and compared using the Chi square test. The annualized age-specific incidence rates of MS were calculated each year, using predefined age categories. The age specific rates were estimated by dividing the number of incident cases each year by the number of active CHS members in the same age group at mid-years. Incidence rates of MS (age ≥ 60 years) were calculated according to sex and compared at different time periods using Chi square test. Similarly, incidence rate ratios were calculated for each sex separately, and differences between time intervals compared using Chi square test. Slopes were calculated using linear regression to evaluate trends over time. Statistical analysis was performed using IBM SPSS Statistics 28.0 (IBM, New York, NY) and SAS vs. 9.4 (SAS institute, Cary, NC, USA). Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1